|
1
|
Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).
|
Lancet Oncol
|
2009
|
7.67
|
|
2
|
Cost of stroke in the United Kingdom.
|
Age Ageing
|
2009
|
4.82
|
|
3
|
The efficiency frontier approach to economic evaluation of health-care interventions.
|
Health Econ
|
2010
|
3.95
|
|
4
|
The current cost of heart failure to the National Health Service in the UK.
|
Eur J Heart Fail
|
2002
|
3.17
|
|
5
|
Equity, waiting times, and NHS reforms: retrospective study.
|
BMJ
|
2009
|
2.86
|
|
6
|
An economic evaluation of lung transplantation.
|
J Thorac Cardiovasc Surg
|
2002
|
2.29
|
|
7
|
QALYs: the basics.
|
Value Health
|
2009
|
1.99
|
|
8
|
Income-related inequalities in the prevalence of depression and suicidal behaviour: a 10-year trend following economic crisis.
|
World Psychiatry
|
2011
|
1.39
|
|
9
|
Toward a consensus on the QALY.
|
Value Health
|
2009
|
1.30
|
|
10
|
Cost-effectiveness of stroke unit care followed by early supported discharge.
|
Stroke
|
2008
|
1.25
|
|
11
|
In search of a corrected prescription drug elasticity estimate: a meta-regression approach.
|
Health Econ
|
2007
|
0.94
|
|
12
|
A health economic model for evaluating a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in the UK.
|
Cost Eff Resour Alloc
|
2010
|
0.93
|
|
13
|
In defence of our research on competition in England's National Health Service.
|
Lancet
|
2011
|
0.92
|
|
14
|
Persistence despite action? Measuring the patterns of health inequality in England (1997-2007).
|
Health Policy
|
2011
|
0.87
|
|
15
|
Stochastic demand, production responses and hospital costs.
|
J Health Econ
|
2003
|
0.87
|
|
16
|
Allocating funds for cardiovascular disease prevention in light of the NCEP ATP III guidelines.
|
Am J Manag Care
|
2003
|
0.85
|
|
17
|
Is theatre utilization a valid performance indicator for NHS operating theatres?
|
BMC Health Serv Res
|
2008
|
0.83
|
|
18
|
An assessment of the cost of percutaneous pulmonary valve implantation (PPVI) versus surgical pulmonary valve replacement (PVR) in patients with right ventricular outflow tract dysfunction.
|
J Med Econ
|
2011
|
0.83
|
|
19
|
The economics of screening and treatment in type 2 diabetes mellitus.
|
Pharmacoeconomics
|
2003
|
0.81
|
|
20
|
The level of income appears to have no consistent bearing on pharmaceutical prices across countries.
|
Health Aff (Millwood)
|
2011
|
0.81
|
|
21
|
Cost effectiveness of paliperidone palmitate versus risperidone long-acting injectable and olanzapine pamoate for the treatment of patients with schizophrenia in Sweden.
|
J Med Econ
|
2012
|
0.81
|
|
22
|
Cost-effectiveness of highly purified omega-3 polyunsaturated fatty acid ethyl esters in the treatment of chronic heart failure: results of Markov modelling in a UK setting.
|
Eur J Heart Fail
|
2011
|
0.78
|
|
23
|
IQWiG methods--a response to two critiques.
|
Health Econ
|
2010
|
0.77
|
|
24
|
The influence of economic incentives and regulatory factors on the adoption of treatment technologies: a case study of technologies used to treat heart attacks.
|
Health Econ
|
2009
|
0.77
|
|
25
|
Analysis of prices paid by low-income countries - how price sensitive is government demand for medicines?
|
BMC Public Health
|
2014
|
0.75
|
|
26
|
More money for medical research.
|
BMJ
|
2006
|
0.75
|
|
27
|
Professor Gavin Mooney 1943-2012.
|
Health Econ
|
2013
|
0.75
|
|
28
|
Technology diffusion and substitution of medical innovations.
|
Adv Health Econ Health Serv Res
|
2012
|
0.75
|
|
29
|
Publication selection in health policy research: the winner's curse hypothesis.
|
Health Policy
|
2012
|
0.75
|
|
30
|
The European value-pricing game.
|
Expert Rev Pharmacoecon Outcomes Res
|
2012
|
0.75
|